Alnylam Pharmaceuticals, Inc. (ALNY)
Data as of September 4, 2026 · Biotechnology
Stockbruh grade: Mixed 3/5 metrics rated Sunny
What does Alnylam Pharmaceuticals, Inc. do?
Alnylam Pharmaceuticals 🧬 discovers and develops RNA-based therapies for genetic and metabolic diseases 🌱. They have cool products like ONPATTRO, GIVLAARI, and OXLUMO for treating conditions like hereditary neuropathy and liver diseases 🌟. Headquartered in Cambridge, Massachusetts 🏢, they're on a mission to revolutionize healthcare with the power of RNA interference ✨!.
Key Numbers
| Metric | Rating | What it means |
|---|
| Returns (5Y) | ⛅ Moderate | 5-year price performance |
| Profitability | ☀️ Strong | Net margin & return on equity |
| Growth | ☀️ Strong | Revenue & earnings trend |
| Earnings | ☀️ Strong | EPS vs analyst expectations |
| Cash & Debt | ⛅ Moderate | Balance sheet strength |
| Price | $264.50 | Market Cap | — |
| Exchange | NASDAQ Global Select | | |
Plain-English Analysis
What's it worth?
Performance has been moderate. Sign up free to see Stockbruh's full valuation analysis including price ratios and plain-English commentary.
How the business works
Alnylam Pharmaceuticals 🧬 discovers and develops RNA-based therapies for genetic and metabolic diseases 🌱. They have cool products like ONPATTRO, GIVLAARI, and OXLUMO for treating conditions like hereditary neuropathy and liver diseases 🌟. Sign up free for competitor and revenue breakdown ↗
Are they building the future?
Revenue and earnings are trending upward — Alnylam Pharmaceuticals, Inc. appears to be growing. Sign up free for the full growth analysis including year-over-year comparisons and R&D investment data.
What's ahead?
Recent earnings have been strong, meeting or beating analyst expectations. Sign up free for earnings history, EPS trends, and what analysts are forecasting next.